Keith Regnante serves as the Chief Financial Officer at Keros Therapeutics Inc., a biotechnology company focused on developing treatments for hematological and musculoskeletal disorders. With a robust background in finance and strategic planning within the life sciences industry, Regnante brings a wealth of experience to his role. Prior to joining Keros Therapeutics, he held the position of CFO at Saniona, a clinical-stage biopharmaceutical company, where he was instrumental in steering the company through significant growth phases and strategic initiatives. Regnante's career also includes a notable tenure at Alexion Pharmaceuticals, where he served as Vice President of Finance and Corporate Controller. During his time at Alexion, he played a key role in the company's financial operations and was involved in multiple successful product launches that contributed to the company's growth and market expansion. His expertise in financial management, coupled with his strategic vision, has been pivotal in driving Keros Therapeutics' financial strategy and supporting the company's mission to develop transformative therapies. As CFO of Keros Therapeutics, Keith Regnante is responsible for overseeing the company's financial operations, including financial planning and analysis, accounting, and investor relations. His leadership has been crucial in securing funding and managing the company's resources efficiently, ensuring that Keros can continue to advance its pipeline of innovative treatments. Regnante's strategic foresight and dedication to the company's goals make him an invaluable member of the Keros team, guiding the company towards achieving its long-term objectives in the biotechnology sector.